Xiaojuan Li

7.8k total citations · 1 hit paper
247 papers, 5.7k citations indexed

About

Xiaojuan Li is a scholar working on Molecular Biology, Immunology and Cancer Research. According to data from OpenAlex, Xiaojuan Li has authored 247 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Molecular Biology, 47 papers in Immunology and 43 papers in Cancer Research. Recurrent topics in Xiaojuan Li's work include Tryptophan and brain disorders (25 papers), Bone Metabolism and Diseases (24 papers) and Stress Responses and Cortisol (18 papers). Xiaojuan Li is often cited by papers focused on Tryptophan and brain disorders (25 papers), Bone Metabolism and Diseases (24 papers) and Stress Responses and Cortisol (18 papers). Xiaojuan Li collaborates with scholars based in China, United States and Macao. Xiaojuan Li's co-authors include Jiaxu Chen, Qingyu Ma, Shuwen Liu, Yueyun Liu, Wenzhi Hao, Fanxiu Zhu, Xiangzhou Zeng, Zhiyi Yan, Hui Zhong and Weili Bao and has published in prestigious journals such as Blood, The Journal of Immunology and PLoS ONE.

In The Last Decade

Xiaojuan Li

236 papers receiving 5.6k citations

Hit Papers

Gut dysbiosis induces the development of depression-like ... 2024 2026 2025 2024 10 20 30 40 50

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaojuan Li China 41 2.7k 828 812 726 651 247 5.7k
Xiang Xu China 48 3.6k 1.4× 1.5k 1.8× 1.2k 1.4× 1.1k 1.6× 218 0.3× 290 7.6k
Donghyun Joo United States 10 2.6k 1.0× 1.7k 2.1× 568 0.7× 772 1.1× 195 0.3× 10 6.4k
Christos Tsatsanis Greece 47 3.0k 1.1× 2.7k 3.2× 801 1.0× 1.4k 1.9× 210 0.3× 131 8.0k
Narayanan Parameswaran United States 36 2.7k 1.0× 837 1.0× 403 0.5× 284 0.4× 109 0.2× 99 4.7k
Burkhard Kleuser Germany 48 6.1k 2.3× 1.2k 1.5× 519 0.6× 634 0.9× 161 0.2× 235 9.6k
Mitsuru Seishima Japan 43 2.0k 0.8× 1.5k 1.8× 502 0.6× 404 0.6× 1.2k 1.8× 176 6.4k
Peter W. Jurutka United States 42 2.2k 0.8× 622 0.8× 671 0.8× 198 0.3× 122 0.2× 122 7.9k
Athena Chalaris Germany 32 1.9k 0.7× 2.1k 2.6× 1.8k 2.2× 611 0.8× 187 0.3× 46 6.3k
Hiroshi Okamoto Japan 47 2.2k 0.8× 951 1.1× 1.1k 1.3× 443 0.6× 86 0.1× 243 8.0k
Xiaohua Li China 44 3.9k 1.5× 574 0.7× 941 1.2× 1.5k 2.0× 277 0.4× 251 7.3k

Countries citing papers authored by Xiaojuan Li

Since Specialization
Citations

This map shows the geographic impact of Xiaojuan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaojuan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaojuan Li more than expected).

Fields of papers citing papers by Xiaojuan Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaojuan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaojuan Li. The network helps show where Xiaojuan Li may publish in the future.

Co-authorship network of co-authors of Xiaojuan Li

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaojuan Li. A scholar is included among the top collaborators of Xiaojuan Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaojuan Li. Xiaojuan Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zou, Binhua, et al.. (2025). Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseases. Pharmacological Research. 219. 107903–107903.
2.
Xu, Xiyuan, et al.. (2025). Neutrophil Extracellular Traps in Sepsis and Sepsis-Related Organ Dysfunction. ImmunoTargets and Therapy. Volume 14. 1373–1393.
3.
Li, Xiaojuan, et al.. (2024). HJURP inhibits sensitivity to ferroptosis inducers in prostate cancer cells by enhancing the peroxidase activity of PRDX1. Redox Biology. 77. 103392–103392. 8 indexed citations
4.
Chen, Yan, Fengsheng Chen, Lishan Chen, et al.. (2024). Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor. Phytomedicine. 129. 155688–155688. 7 indexed citations
5.
He, Weili, Yan Chen, Lihong Li, et al.. (2024). Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction. Journal of Advanced Research. 69. 399–411. 10 indexed citations
6.
Wang, Xihong, Qingyu Ma, Xuan Zhou, et al.. (2024). Xiaoyao Pills, a Chinese patent medicine, treats mild and moderate depression: A randomized clinical trial combined with DNA methylation analysis. Phytomedicine. 130. 155660–155660. 8 indexed citations
7.
Lin, Bo-Wen, et al.. (2023). Y-box binding protein 1 promotes chromatin accessibility to aggravate liver fibrosis. Cellular Signalling. 109. 110750–110750. 9 indexed citations
8.
Huang, Long, Xiaojuan Li, Fuming Xu, & Fuhong Li. (2023). Consequences of scarcity: the impact of perceived scarcity on executive functioning and its neural basis. Frontiers in Neuroscience. 17. 1158544–1158544. 3 indexed citations
10.
Bo, Zongyi, et al.. (2023). Ginkgolic acid inhibits the replication of pseudorabies virus in vitro and in vivo by suppressing the transcription of viral late genes. Research in Veterinary Science. 164. 105033–105033. 3 indexed citations
11.
Qiu, Wenqi, Qian Wu, Kaiwen Zhang, et al.. (2023). Xiaoyaosan ameliorates depressive-like behavior and susceptibility to glucose intolerance in rat: involvement of LepR-STAT3/PI3K pathway in hypothalamic arcuate nucleus. BMC Complementary Medicine and Therapies. 23(1). 116–116. 8 indexed citations
12.
Liu, Chenyue, Yueyun Liu, Qingyu Ma, et al.. (2021). Xiaoyaosan Alleviates Hippocampal Glutamate-Induced Toxicity in the CUMS Rats via NR2B and PI3K/Akt Signaling Pathway. Frontiers in Pharmacology. 12. 586788–586788. 56 indexed citations
13.
Yu, Meng, Ruili Li, Yaning Cui, et al.. (2020). The RALF1-FERONIA interaction modulates endocytosis to mediate control of root growth in Arabidopsis. Development. 147(13). 48 indexed citations
14.
Wang, Jun, et al.. (2019). MicroRNA‐488 inhibits proliferation and glycolysis in human prostate cancer cells by regulating PFKFB3. FEBS Open Bio. 9(10). 1798–1807. 20 indexed citations
15.
Ding, Xiufang, Yan Liu, Zhiyi Yan, et al.. (2017). Involvement of Normalized Glial Fibrillary Acidic Protein Expression in the Hippocampi in Antidepressant‐Like Effects of Xiaoyaosan on Chronically Stressed Mice. Evidence-based Complementary and Alternative Medicine. 2017(1). 1960584–1960584. 25 indexed citations
17.
Fu, Bishi, Ersheng Kuang, Wenwei Li, et al.. (2014). Activation of p90 Ribosomal S6 Kinases by ORF45 of Kaposi's Sarcoma-Associated Herpesvirus Is Critical for Optimal Production of Infectious Viruses. Journal of Virology. 89(1). 195–207. 33 indexed citations
18.
Chen, Zhiwen, Zixiang Wu, Hongxun Sang, et al.. (2011). [Effect of aspirin administration for the treatment of osteoporosis in ovariectomized rat model].. PubMed. 91(13). 925–9. 10 indexed citations
19.
Hu, Yiping, Xiaojuan Li, & Shuwen Liu. (2010). [Effects of ConA on early activation and function of CD4+ CD25+ Treg cells in mice].. PubMed. 26(2). 118–20, 124. 2 indexed citations
20.
Chen, Jifan, et al.. (2003). [Effect of overall alkali of Tongbiling on CD69 expression activated mouse T lymphocytes].. PubMed. 19(1). 93–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026